AI English summary of an SEC filing — figures as filed
Bristol Myers Squibb BMYThe company said it completed its acquisition of Karuna Therapeutics, Inc. on March 18, 2024. Each share of Karuna common stock outstanding, excluding certain excluded shares, was converted into the right to receive $330.00 in cash, without interest and subject to any required withholding taxes, for a total of 1 shares.
Key points
AI summaryThe company said it completed its acquisition of Karuna Therapeutics, Inc. on March 18, 2024. Each share of Karuna common stock outstanding, excluding certain excluded shares, was converted into the right to receive $330.00 in cash, without interest and subject to any required withholding taxes, for a total of 1 shares.
Bristol Myers Squibb said the completion of the acquisition meant Karuna shares stopped trading on the Nasdaq Global Select Market and Karuna became a wholly owned subsidiary. The company also said the PDUFA date for KarXT in adult schizophrenia is September 26, 2024.
The company said it will account for the transaction as an asset acquisition, with a one-time, non-deductible Acquired IPR&D charge of about $12 billion. It said the charge will affect both Q1 2024 and full-year GAAP and non-GAAP EPS by about $5.93 per share.
The company said the transaction is expected to dilute its non-GAAP diluted EPS by about $0.30 in 2024, mainly due to financing costs from a recently completed new debt issuance. It said it will provide an update to its outlook when it reports Q1 results on February 2, 2024, April 25, 2024.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Bristol Myers Squibb Completes Karuna Therapeutics Acquisition for $330.00 Cash per Share
The company said it completed its acquisition of Karuna Therapeutics, Inc. on March 18, 2024. Each share of Karuna common stock outstanding, excluding certain excluded shares, was converted into the right to receive $330.00 in cash, without interest and subject to any required withholding taxes, for a total of 1 shares.
Source · Based on the filing body and exhibits
Karuna Becomes Wholly Owned Subsidiary; KarXT PDUFA Date Set
Bristol Myers Squibb said the completion of the acquisition meant Karuna shares stopped trading on the Nasdaq Global Select Market and Karuna became a wholly owned subsidiary. The company also said the PDUFA date for KarXT in adult schizophrenia is September 26, 2024.
Source · Based on the filing body and exhibits
Acquired IPR&D Charge of About $12 billion and Impact of About $5.93 per Share
The company said it will account for the transaction as an asset acquisition, with a one-time, non-deductible Acquired IPR&D charge of about $12 billion. It said the charge will affect both Q1 2024 and full-year GAAP and non-GAAP EPS by about $5.93 per share.
Source · Based on the filing body and exhibits
2024 Non-GAAP Diluted EPS Dilution of About $0.30 and Outlook Update Timing
The company said the transaction is expected to dilute its non-GAAP diluted EPS by about $0.30 in 2024, mainly due to financing costs from a recently completed new debt issuance. It said it will provide an update to its outlook when it reports Q1 results on February 2, 2024, April 25, 2024.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…